{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:09:45Z","timestamp":1793416185473,"version":"4.5.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012269","name":"Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province","doi-asserted-by":"crossref","award":["2019WK2081"],"award-info":[{"award-number":["2019WK2081"]}],"id":[{"id":"10.13039\/501100012269","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Project for leading talents in science and technology in Hunan province","award":["2019RS3003"],"award-info":[{"award-number":["2019RS3003"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2019-I2M-5-033"],"award-info":[{"award-number":["2019-I2M-5-033"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12016-020-08831-4","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T06:02:53Z","timestamp":1610690573000},"page":"273-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review"],"prefix":"10.1007","volume":"62","author":[{"given":"Ming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr H.","family":"Sawalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"8831_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa297","author":"A Vanhaecke","year":"2020","unstructured":"Vanhaecke A, De Schepper S, Paolino S, Heeman L, Callens H, Gutermuth J, Nguyen S, Cutolo M, Smith V (2020) Coexistence of systemic and localized scleroderma: a systematic literature review and observational cohort study. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keaa297","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"8831_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","volume":"24","author":"J Barnes","year":"2012","unstructured":"Barnes J, Mayes MD (2012) Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 24(2):165\u2013170. https:\/\/doi.org\/10.1097\/BOR.0b013e32834ff2e8","journal-title":"Curr Opin Rheumatol"},{"key":"8831_CR3","unstructured":"Adigun R, Goyal A, Bansal P, Hariz A (2020) Systemic Sclerosis (CREST syndrome). In: StatPearls. Treasure Island (FL)"},{"key":"8831_CR4","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, Varga J (2015) Systemic sclerosis. Nat Rev Dis Primers 1:15002. https:\/\/doi.org\/10.1038\/nrdp.2015.2","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"8831_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3899\/jrheum.120725","volume":"40","author":"A De Lauretis","year":"2013","unstructured":"De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA (2013) Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 40(4):435\u2013446. https:\/\/doi.org\/10.3899\/jrheum.120725","journal-title":"J Rheumatol"},{"issue":"2","key":"8831_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/ddg.12724","volume":"14","author":"A Kreuter","year":"2016","unstructured":"Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A, Aberer E, Scharffetter-Kochanek K, Horneff G, Reil E, Weberschock T, Hunzelmann N (2016) German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges 14(2):199\u2013216. https:\/\/doi.org\/10.1111\/ddg.12724","journal-title":"J Dtsch Dermatol Ges"},{"key":"8831_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jaut.2019.04.008","volume":"101","author":"JS Mertens","year":"2019","unstructured":"Mertens JS, de Jong E, van den Hoogen LL, Wienke J, Thurlings RM, Seyger MMB, Hoppenreijs E, Wijngaarde CA, van Vlijmen-Willems I, van den Bogaard E, Giovannone B, van Wijk F, van Royen-Kerkhof A, Marut W, Radstake TRD (2019) The identification of CCL18 as biomarker of disease activity in localized scleroderma. J Autoimmun 101:86\u201393. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.008","journal-title":"J Autoimmun"},{"key":"8831_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaut.2017.12.015","volume":"89","author":"E Chouri","year":"2018","unstructured":"Chouri E, Servaas NH, Bekker CPJ, Affandi AJ, Cossu M, Hillen MR, Angiolilli C, Mertens JS, van den Hoogen LL, Silva-Cardoso S, van der Kroef M, Vazirpanah N, Wichers CGK, Carvalheiro T, Blokland SLM, Giovannone B, Porretti L, Marut W, Vigone B, van Roon JAG, Beretta L, Rossato M, Radstake T (2018) Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J Autoimmun 89:162\u2013170. https:\/\/doi.org\/10.1016\/j.jaut.2017.12.015","journal-title":"J Autoimmun"},{"key":"8831_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaut.2017.05.004","volume":"83","author":"PS Tsou","year":"2017","unstructured":"Tsou PS, Sawalha AH (2017) Unfolding the pathogenesis of scleroderma through genomics and epigenomics. J Autoimmun 83:73\u201394. https:\/\/doi.org\/10.1016\/j.jaut.2017.05.004","journal-title":"J Autoimmun"},{"key":"8831_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaut.2015.07.005","volume":"64","author":"L Bossini-Castillo","year":"2015","unstructured":"Bossini-Castillo L, Lopez-Isac E, Martin J (2015) Immunogenetics of systemic sclerosis: defining heritability, functional variants and shared-autoimmunity pathways. J Autoimmun 64:53\u201365. https:\/\/doi.org\/10.1016\/j.jaut.2015.07.005","journal-title":"J Autoimmun"},{"issue":"4","key":"8831_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.clindermatol.2018.04.004","volume":"36","author":"DR Pearson","year":"2018","unstructured":"Pearson DR, Werth VP, Pappas-Taffer L (2018) Systemic sclerosis: current concepts of skin and systemic manifestations. Clin Dermatol 36(4):459\u2013474. https:\/\/doi.org\/10.1016\/j.clindermatol.2018.04.004","journal-title":"Clin Dermatol"},{"issue":"1","key":"8831_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","volume":"35","author":"VD Steen","year":"2005","unstructured":"Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35\u201342. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.03.005","journal-title":"Semin Arthritis Rheum"},{"key":"8831_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2013.11.004","volume":"48\u201349","author":"M Hudson","year":"2014","unstructured":"Hudson M, Fritzler MJ (2014) Diagnostic criteria of systemic sclerosis. J Autoimmun 48\u201349:38\u201341. https:\/\/doi.org\/10.1016\/j.jaut.2013.11.004","journal-title":"J Autoimmun"},{"issue":"11","key":"8831_CR14","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1080\/21645515.2018.1491508","volume":"14","author":"CG Katsiari","year":"2018","unstructured":"Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI (2018) Immunotherapy of systemic sclerosis. Hum Vaccin Immunother 14(11):2559\u20132567. https:\/\/doi.org\/10.1080\/21645515.2018.1491508","journal-title":"Hum Vaccin Immunother"},{"key":"8831_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clim.2017.09.015","volume":"186","author":"PF Dellaripa","year":"2018","unstructured":"Dellaripa PF (2018) Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment. Clin Immunol 186:71\u201373. https:\/\/doi.org\/10.1016\/j.clim.2017.09.015","journal-title":"Clin Immunol"},{"issue":"2","key":"8831_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0889-857x(03)00016-4","volume":"29","author":"VD Steen","year":"2003","unstructured":"Steen VD (2003) Scleroderma renal crisis. Rheum Dis Clin North Am 29(2):315\u2013333. https:\/\/doi.org\/10.1016\/s0889-857x(03)00016-4","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"8831_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Muller-Ladner U, Coauthors E (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8831_CR18","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/14397595.2016.1270796","volume":"27","author":"M Iudici","year":"2017","unstructured":"Iudici M (2017) What should clinicians know about the use of glucocorticoids in systemic sclerosis? Mod Rheumatol 27(6):919\u2013923. https:\/\/doi.org\/10.1080\/14397595.2016.1270796","journal-title":"Mod Rheumatol"},{"issue":"5","key":"8831_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, Co-Authors E (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68(5):620\u2013628. https:\/\/doi.org\/10.1136\/ard.2008.096677","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"8831_CR20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/1756-185X.12952","volume":"20","author":"A Fernandez Morales","year":"2017","unstructured":"Fernandez Morales A, Iniesta N, Fernandez-Codina A, Vaz de Cunha J, Perez Romero T, Hurtado Garcia R, Simeon-Aznar CP, Fonollosa V, Cervera R, Espinosa G (2017) Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. Int J Rheum Dis 20(10):1582\u20131592. https:\/\/doi.org\/10.1111\/1756-185X.12952","journal-title":"Int J Rheum Dis"},{"issue":"13","key":"8831_CR21","first-page":"2390","volume":"125","author":"XM Leng","year":"2012","unstructured":"Leng XM, Sun XF, Zhang X, Zhang W, Li MT, Zeng XF (2012) Systemic sclerosis with portal hypertensive ascites responded to corticosteroid treatment. Chin Med J (Engl) 125(13):2390\u20132392","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"8831_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","volume":"20","author":"S Adler","year":"2018","unstructured":"Adler S, Huscher D, Siegert E, Allanore Y, Czirjak L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G, network Ec-wobotDprgwtE (2018) Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther 20(1):17. https:\/\/doi.org\/10.1186\/s13075-018-1517-z","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"8831_CR23","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/art.30438","volume":"63","author":"MD Roth","year":"2011","unstructured":"Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, Elashoff RM, Scleroderma Lung Study Research G (2011) Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 63(9):2797\u20132808. https:\/\/doi.org\/10.1002\/art.30438","journal-title":"Arthritis Rheum"},{"issue":"11","key":"8831_CR24","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fernandez-Codina","year":"2018","unstructured":"Fernandez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm G (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 70(11):1820\u20131828. https:\/\/doi.org\/10.1002\/art.40560","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"8831_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.semarthrit.2019.06.012","volume":"50","author":"FA Mendoza","year":"2020","unstructured":"Mendoza FA, Lee-Ching C, Jimenez SA (2020) Recurrence of progressive skin involvement following discontinuation or dose reduction of mycophenolate mofetil treatment in patients with diffuse systemic sclerosis. Semin Arthritis Rheum 50(1):135\u2013139. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.012","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"8831_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study III (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"issue":"1","key":"8831_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.31138\/mjr.30.1.33","volume":"30","author":"D Daoussis","year":"2019","unstructured":"Daoussis D, Liossis SN (2019) Treatment of systemic sclerosis associated fibrotic manifestations: current options and future directions. Mediterr J Rheumatol 30(1):33\u201337. https:\/\/doi.org\/10.31138\/mjr.30.1.33","journal-title":"Mediterr J Rheumatol"},{"issue":"12","key":"8831_CR28","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962\u20133970. https:\/\/doi.org\/10.1002\/art.22204","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8831_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14397595.2019.1640343","volume":"30","author":"JN Zheng","year":"2020","unstructured":"Zheng JN, Yang QR, Zhu GQ, Pan L, Xia JX, Wang Q (2020) Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: a Bayesian network analysis. Mod Rheumatol 30(4):687\u2013695. https:\/\/doi.org\/10.1080\/14397595.2019.1640343","journal-title":"Mod Rheumatol"},{"issue":"7","key":"8831_CR30","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","volume":"76","author":"AL Herrick","year":"2017","unstructured":"Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirjak L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt O, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Muller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanc M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 76(7):1207\u20131218. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210503","journal-title":"Ann Rheum Dis"},{"key":"8831_CR31","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.jaut.2020.102526","volume":"113","author":"JC Worrell","year":"2020","unstructured":"Worrell JC, O\u2019Reilly S (2020) Bi-directional communication: conversations between fibroblasts and immune cells in systemic sclerosis. J Autoimmun 113:102526. https:\/\/doi.org\/10.1016\/j.jaut.2020.102526","journal-title":"J Autoimmun"},{"issue":"2","key":"8831_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled. Pilot Trial Arthritis Rheumatol 70(2):308\u2013316. https:\/\/doi.org\/10.1002\/art.40358","journal-title":"Pilot Trial Arthritis Rheumatol"},{"issue":"7","key":"8831_CR33","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellvi I, Airo P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, Lopez-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanorefor En, Y (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78(7):979\u2013987. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214816","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"8831_CR34","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 57(12):2106\u20132113. https:\/\/doi.org\/10.1093\/rheumatology\/key213","journal-title":"Rheumatology (Oxford)"},{"key":"8831_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa193","author":"F Zulian","year":"2020","unstructured":"Zulian F, Dal Pozzolo R, Meneghel A, Castaldi B, Marcolongo R, Caforio ALP, Martini G (2020) Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keaa193","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"8831_CR36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/14712598.2019.1665018","volume":"19","author":"JY Jung","year":"2019","unstructured":"Jung JY, Kim JW, Kim HA, Suh CH (2019) Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 19(10):979\u2013986. https:\/\/doi.org\/10.1080\/14712598.2019.1665018","journal-title":"Expert Opin Biol Ther"},{"key":"8831_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa136","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, De Luca G, Lazzaroni MG, Zanatta E, Bosello SL, De Santis M, Cariddi A, Bruni C, Selmi C, Gremese E, Matucci-Cerinic M, Doria A, Airo P, Dagna L (2020) Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keaa136","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"8831_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y (2014) Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 141(2):125\u2013139. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.004","journal-title":"Pharmacol Ther"},{"issue":"4","key":"8831_CR39","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1186\/ar4672","volume":"16","author":"L Desallais","year":"2014","unstructured":"Desallais L, Avouac J, Frechet M, Elhai M, Ratsimandresy R, Montes M, Mouhsine H, Do H, Zagury JF, Allanore Y (2014) Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 16(4):R157. https:\/\/doi.org\/10.1186\/ar4672","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"8831_CR40","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","volume":"49","author":"Y Shima","year":"2010","unstructured":"Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T, Arimitsu J, Narazaki M, Hagihara K, Ogata A, Katayama I, Kawase I, Kishimoto T, Tanaka T (2010) The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 49(12):2408\u20132412. https:\/\/doi.org\/10.1093\/rheumatology\/keq275","journal-title":"Rheumatology (Oxford)"},{"issue":"10038","key":"8831_CR41","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Muller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387(10038):2630\u20132640. https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"issue":"2","key":"8831_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Muller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77(2):212\u2013220. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211682","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"8831_CR43","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","volume":"75","author":"M Ponsoye","year":"2016","unstructured":"Ponsoye M, Frantz C, Ruzehaji N, Nicco C, Elhai M, Ruiz B, Cauvet A, Pezet S, Brandely ML, Batteux F, Allanore Y, Avouac J (2016) Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann Rheum Dis 75(12):2142\u20132149. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208213","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"8831_CR44","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/rheumatology\/keh303","volume":"43","author":"S Sato","year":"2004","unstructured":"Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K (2004) Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 43(10):1261\u20131266. https:\/\/doi.org\/10.1093\/rheumatology\/keh303","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8831_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE (2020) Abatacept in early diffuse cutaneous systemic sclerosis: results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized Placebo-Controlled Trial. Arthritis Rheumatol 72(1):125\u2013136. https:\/\/doi.org\/10.1002\/art.41055","journal-title":"Arthritis Rheumatol"},{"key":"8831_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.12.004","author":"I Castellvi","year":"2020","unstructured":"Castellvi I, Elhai M, Bruni C, Airo P, Jordan S, Beretta L, Codullo V, Montecucco CM, Bokarewa M, Iannonne F, Balbir A, Hsu VM, Distler O, Matucci-Cerinic M, Allanore Y, for En (2020) Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. Semin Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.12.004","journal-title":"Semin Arthritis Rheum"},{"issue":"41","key":"8831_CR47","doi-asserted-by":"publisher","first-page":"7062","DOI":"10.3748\/wjg.v19.i41.7062","volume":"19","author":"XP Tian","year":"2013","unstructured":"Tian XP, Zhang X (2013) Gastrointestinal complications of systemic sclerosis. World J Gastroenterol 19(41):7062\u20137068. https:\/\/doi.org\/10.3748\/wjg.v19.i41.7062","journal-title":"World J Gastroenterol"},{"issue":"12","key":"8831_CR48","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","volume":"10","author":"R Lafyatis","year":"2014","unstructured":"Lafyatis R (2014) Transforming growth factor beta\u2013at the centre of systemic sclerosis. Nat Rev Rheumatol 10(12):706\u2013719. https:\/\/doi.org\/10.1038\/nrrheum.2014.137","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"8831_CR49","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, Nakerakanti S, York M, Farina G, Whitfield ML, Spiera RF, Christmann RB, Gordon JK, Weinberg J, Simms RW, Lafyatis R (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125(7):2795\u20132807. https:\/\/doi.org\/10.1172\/JCI77958","journal-title":"J Clin Invest"},{"issue":"1","key":"8831_CR50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/art.22289","volume":"56","author":"CP Denton","year":"2007","unstructured":"Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR, Cat-192 Study G, Scleroderma Clinical Trials C (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192. Arthritis Rheum 56(1):323\u2013333. https:\/\/doi.org\/10.1002\/art.22289","journal-title":"Arthritis Rheum"},{"key":"8831_CR51","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/978-1-62703-586-6_18","volume":"1060","author":"M Blank","year":"2014","unstructured":"Blank M, Bashi T, Shoenfeld Y (2014) Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases. Methods Mol Biol 1060:353\u2013361. https:\/\/doi.org\/10.1007\/978-1-62703-586-6_18","journal-title":"Methods Mol Biol"},{"issue":"2 Suppl 76","key":"8831_CR52","first-page":"166","volume":"31","author":"TM Frech","year":"2013","unstructured":"Frech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, Hinchcliff ME, Steen V, Khanna D, Kayser C, Domsic RT (2013) Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 31(2 Suppl 76):166\u2013171","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"8831_CR53","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/art.10363","volume":"46","author":"M Blank","year":"2002","unstructured":"Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O (2002) The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 46(6):1689\u20131690. https:\/\/doi.org\/10.1002\/art.10363","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8831_CR54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","volume":"55","author":"J Raja","year":"2016","unstructured":"Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH (2016) Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford) 55(1):115\u2013119. https:\/\/doi.org\/10.1093\/rheumatology\/kev318","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8831_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","volume":"16","author":"S Sanges","year":"2017","unstructured":"Sanges S, Riviere S, Mekinian A, Martin T, Le Quellec A, Chatelus E, Lescoat A, Jego P, Cazalets C, Quemeneur T, Le Gouellec N, Senet P, Frances C, Deroux A, Imbert B, Fain O, Boukari L, Sene T, Deligny C, Mathian A, Agard C, Pugnet G, Speca S, Dubucquoi S, Hatron PY, Hachulla E, Launay D (2017) Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev 16(4):377\u2013384. https:\/\/doi.org\/10.1016\/j.autrev.2017.02.008","journal-title":"Autoimmun Rev"},{"key":"8831_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2018.12.006","volume":"199","author":"JP Gomes","year":"2019","unstructured":"Gomes JP, Santos L, Shoenfeld Y (2019) Intravenous immunoglobulin (IVIG) in the vanguard therapy of systemic sclerosis. Clin Immunol 199:25\u201328. https:\/\/doi.org\/10.1016\/j.clim.2018.12.006","journal-title":"Clin Immunol"},{"issue":"Suppl 5","key":"8831_CR57","doi-asserted-by":"publisher","first-page":"v2","DOI":"10.1093\/rheumatology\/ken265","volume":"47","author":"M Trojanowska","year":"2008","unstructured":"Trojanowska M (2008) Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v2-4. https:\/\/doi.org\/10.1093\/rheumatology\/ken265","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"8831_CR58","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/BOR.0b013e32833f1105","volume":"22","author":"JK Gordon","year":"2010","unstructured":"Gordon JK, Spiera RF (2010) Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Curr Opin Rheumatol 22(6):690\u2013695. https:\/\/doi.org\/10.1097\/BOR.0b013e32833f1105","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"8831_CR59","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/ard.2010.143974","volume":"70","author":"RF Spiera","year":"2011","unstructured":"Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK (2011) Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70(6):1003\u20131009. https:\/\/doi.org\/10.1136\/ard.2010.143974","journal-title":"Ann Rheum Dis"},{"key":"8831_CR60","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"3","author":"PW Manley","year":"1804","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M (1804) Fabbro D (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 3:445\u2013453. https:\/\/doi.org\/10.1016\/j.bbapap.2009.11.008","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"8831_CR61","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O\u2019Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540\u20133546. https:\/\/doi.org\/10.1182\/blood-2007-03-080689","journal-title":"Blood"},{"key":"8831_CR62","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","volume":"17","author":"JK Gordon","year":"2015","unstructured":"Gordon JK, Martyanov V, Magro C, Wildman HF, Wood TA, Huang WT, Crow MK, Whitfield ML, Spiera RF (2015) Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res Ther 17:213. https:\/\/doi.org\/10.1186\/s13075-015-0721-3","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"8831_CR63","doi-asserted-by":"publisher","first-page":"e0187580","DOI":"10.1371\/journal.pone.0187580","volume":"12","author":"V Martyanov","year":"2017","unstructured":"Martyanov V, Kim GJ, Hayes W, Du S, Ganguly BJ, Sy O, Lee SK, Bogatkevich GS, Schieven GL, Schiopu E, Marangoni RG, Goldin J, Whitfield ML, Varga J (2017) Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS ONE 12(11):e0187580. https:\/\/doi.org\/10.1371\/journal.pone.0187580","journal-title":"PLoS ONE"},{"issue":"5","key":"8831_CR64","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45(5):1434\u20131445. https:\/\/doi.org\/10.1183\/09031936.00174914","journal-title":"Eur Respir J"},{"key":"8831_CR65","doi-asserted-by":"publisher","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, Investigators ST (2019) Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 380 (26):2518-2528. doi:https:\/\/doi.org\/10.1056\/NEJMoa1903076","DOI":"10.1056\/NEJMoa1903076"},{"key":"8831_CR66","doi-asserted-by":"publisher","unstructured":"Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, investigators St (2020) Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Ann Rheum Dis. doi:https:\/\/doi.org\/10.1136\/annrheumdis-2020-217331","DOI":"10.1136\/annrheumdis-2020-217331"},{"issue":"3","key":"8831_CR67","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jdermsci.2014.02.002","volume":"74","author":"Z Tamaki","year":"2014","unstructured":"Tamaki Z, Asano Y, Kubo M, Ihn H, Tada Y, Sugaya M, Kadono T, Sato S (2014) Effects of the immunosuppressant rapamycin on the expression of human alpha2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts. J Dermatol Sci 74(3):251\u2013259. https:\/\/doi.org\/10.1016\/j.jdermsci.2014.02.002","journal-title":"J Dermatol Sci"},{"issue":"1","key":"8831_CR68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/1346-8138.13026","volume":"43","author":"K Yanaba","year":"2016","unstructured":"Yanaba K (2016) Strategy for treatment of fibrosis in systemic sclerosis: present and future. J Dermatol 43(1):46\u201355. https:\/\/doi.org\/10.1111\/1346-8138.13026","journal-title":"J Dermatol"},{"issue":"12","key":"8831_CR69","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1002\/art.24986","volume":"60","author":"TI Su","year":"2009","unstructured":"Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, Clements PJ (2009) Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 60(12):3821\u20133830. https:\/\/doi.org\/10.1002\/art.24986","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8831_CR70","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1182\/blood.v98.5.1616","volume":"98","author":"H Das","year":"2001","unstructured":"Das H, Wang L, Kamath A, Bukowski JF (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98(5):1616\u20131618. https:\/\/doi.org\/10.1182\/blood.v98.5.1616","journal-title":"Blood"},{"issue":"2","key":"8831_CR71","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384\u2013392","journal-title":"Blood"},{"issue":"2","key":"8831_CR72","first-page":"283","volume":"32","author":"V Riccieri","year":"2005","unstructured":"Riccieri V, Parisi G, Spadaro A, Scrivo R, Barone F, Moretti T, Bernardini G, Strom R, Taccari E, Valesini G (2005) Reduced circulating natural killer T cells and gamma\/delta T cells in patients with systemic sclerosis. J Rheumatol 32(2):283\u2013286","journal-title":"J Rheumatol"},{"issue":"3","key":"8831_CR73","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.4049\/jimmunol.175.3.1593","volume":"175","author":"R Casetti","year":"2005","unstructured":"Casetti R, Perretta G, Taglioni A, Mattei M, Colizzi V, Dieli F, D\u2019Offizi G, Malkovsky M, Poccia F (2005) Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2. J Immunol 175(3):1593\u20131598. https:\/\/doi.org\/10.4049\/jimmunol.175.3.1593","journal-title":"J Immunol"},{"issue":"4","key":"8831_CR74","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.4049\/jimmunol.174.4.1801","volume":"174","author":"K Takagi","year":"2005","unstructured":"Takagi K, Takagi M, Kanangat S, Warrington KJ, Shigemitsu H, Postlethwaite AE (2005) Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol 174(4):1801\u20131810. https:\/\/doi.org\/10.4049\/jimmunol.174.4.1801","journal-title":"J Immunol"},{"issue":"3","key":"8831_CR75","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2249.2006.03216.x","volume":"146","author":"LD Carbone","year":"2006","unstructured":"Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, Ingels J, Postlethwaite AE (2006) Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 146(3):371\u2013380. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03216.x","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"8831_CR76","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","volume":"79","author":"D Khanna","year":"2020","unstructured":"Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Becvar R, Czirjak L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szucs G, Truchetet ME, Wosnitza M, Laapas K, de Oliveira PJ, Yao Z, Kramer F, Distler O (2020) Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis 79(5):618\u2013625. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216823","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"8831_CR77","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.rmed.2016.09.011","volume":"122","author":"O Distler","year":"2017","unstructured":"Distler O, Pope J, Denton C, Allanore Y, Matucci-Cerinic M, de Oliveira PJ, Khanna D (2017) RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. Respir Med 122(Suppl 1):S14\u2013S17. https:\/\/doi.org\/10.1016\/j.rmed.2016.09.011","journal-title":"Respir Med"},{"issue":"9790","key":"8831_CR78","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, Craig R, Hirano I, Marshall K, Ruderman E, Jovanovic B, Milanetti F, Jain S, Boyce K, Morgan A, Carr J, Barr W (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378(9790):498\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(11)60982-3","journal-title":"Lancet"},{"issue":"24","key":"8831_CR79","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kotter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quere I, Rich E, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socie G, Gratwohl A, Tyndall A, Group EESS (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490\u20132498. https:\/\/doi.org\/10.1001\/jama.2014.6368","journal-title":"JAMA"},{"issue":"1","key":"8831_CR80","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE, Investigators SS (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378(1):35\u201347. https:\/\/doi.org\/10.1056\/nejmoa1703327","journal-title":"N Engl J Med"},{"key":"8831_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001117","author":"KR Costa-Pereira","year":"2019","unstructured":"Costa-Pereira KR, Guimaraes AL, Moraes DA, Dias JBE, Garcia JT, de Oliveira-Cardoso EA, Zombrilli A, Leopoldo V, Costa TM, Simoes BP, Oliveira MC (2019) Hematopoietic stem cell transplantation improves functional outcomes of systemic sclerosis patients. J Clin Rheumatol. https:\/\/doi.org\/10.1097\/RHU.0000000000001117","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"8831_CR82","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1093\/rheumatology\/kev117","volume":"54","author":"JM van Laar","year":"2015","unstructured":"van Laar JM, Naraghi K, Tyndall A (2015) Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology (Oxford) 54(12):2126\u20132133. https:\/\/doi.org\/10.1093\/rheumatology\/kev117","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"8831_CR83","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.15993","volume":"178","author":"A Eyraud","year":"2018","unstructured":"Eyraud A, Scouppe L, Barnetche T, Forcade E, Lazaro E, Duffau P, Richez C, Seneschal J, Truchetet ME, Fhu A (2018) Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature. Br J Dermatol 178(3):650\u2013658. https:\/\/doi.org\/10.1111\/bjd.15993","journal-title":"Br J Dermatol"},{"issue":"4","key":"8831_CR84","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40259-019-00364-3","volume":"33","author":"A Tyndall","year":"2019","unstructured":"Tyndall A (2019) Hematopoietic stem cell transplantation for systemic sclerosis: review of current status. BioDrugs 33(4):401\u2013409. https:\/\/doi.org\/10.1007\/s40259-019-00364-3","journal-title":"BioDrugs"},{"key":"8831_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaut.2016.03.013","volume":"70","author":"AT Maria","year":"2016","unstructured":"Maria AT, Toupet K, Maumus M, Fonteneau G, Le Quellec A, Jorgensen C, Guilpain P, Noel D (2016) Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. J Autoimmun 70:31\u201339. https:\/\/doi.org\/10.1016\/j.jaut.2016.03.013","journal-title":"J Autoimmun"},{"key":"8831_CR86","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.trsl.2019.02.010","volume":"209","author":"B Korman","year":"2019","unstructured":"Korman B (2019) Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis. Transl Res 209:77\u201389. https:\/\/doi.org\/10.1016\/j.trsl.2019.02.010","journal-title":"Transl Res"},{"issue":"22","key":"8831_CR87","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ, Pulmonary Arterial H, Response to Tadalafil Study G (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22):2894\u20132903. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.839274","journal-title":"Circulation"},{"issue":"6","key":"8831_CR88","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","volume":"42","author":"PJ Clements","year":"1999","unstructured":"Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR (1999) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42(6):1194\u20131203. https:\/\/doi.org\/10.1002\/1529-0131(199906)42:6%3c1194::AID-ANR16%3e3.0.CO;2-7","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8831_CR89","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1172\/JCI111480","volume":"74","author":"SA Jimenez","year":"1984","unstructured":"Jimenez SA, Freundlich B, Rosenbloom J (1984) Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 74(3):1112\u20131116. https:\/\/doi.org\/10.1172\/JCI111480","journal-title":"J Clin Invest"},{"issue":"3","key":"8831_CR90","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0002-9343(89)80150-0","volume":"87","author":"A Kahan","year":"1989","unstructured":"Kahan A, Amor B, Menkes CJ, Strauch G (1989) Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 87(3):273\u2013277. https:\/\/doi.org\/10.1016\/s0002-9343(89)80150-0","journal-title":"Am J Med"},{"issue":"10","key":"8831_CR91","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/art.1780351005","volume":"35","author":"B Freundlich","year":"1992","unstructured":"Freundlich B, Jimenez SA, Steen VD, Medsger TA Jr, Szkolnicki M, Jaffe HS (1992) Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I\/II clinical trial. Arthritis Rheum 35(10):1134\u20131142. https:\/\/doi.org\/10.1002\/art.1780351005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8831_CR92","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","volume":"42","author":"CM Black","year":"1999","unstructured":"Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, Pompon L, Shi-Wen X (1999) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42(2):299\u2013305. https:\/\/doi.org\/10.1002\/1529-0131(199902)42:2%3c299::AID-ANR12%3e3.0.CO;2-R","journal-title":"Arthritis Rheum"},{"issue":"18","key":"8831_CR93","doi-asserted-by":"publisher","first-page":"10681","DOI":"10.1016\/S0021-9258(18)87000-4","volume":"265","author":"EN Unemori","year":"1990","unstructured":"Unemori EN, Amento EP (1990) Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem 265(18):10681\u201310685","journal-title":"J Biol Chem"},{"issue":"3","key":"8831_CR94","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/1523-1747.ep12616665","volume":"99","author":"EN Unemori","year":"1992","unstructured":"Unemori EN, Bauer EA, Amento EP (1992) Relaxin alone and in conjunction with interferon-gamma decreases collagen synthesis by cultured human scleroderma fibroblasts. J Invest Dermatol 99(3):337\u2013342. https:\/\/doi.org\/10.1111\/1523-1747.ep12616665","journal-title":"J Invest Dermatol"},{"issue":"11","key":"8831_CR95","doi-asserted-by":"publisher","first-page":"871","DOI":"10.7326\/0003-4819-132-11-200006060-00004","volume":"132","author":"JR Seibold","year":"2000","unstructured":"Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME (2000) Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 132(11):871\u2013879. https:\/\/doi.org\/10.7326\/0003-4819-132-11-200006060-00004","journal-title":"Ann Intern Med"},{"issue":"6","key":"8831_CR96","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.23501","volume":"58","author":"AE Postlethwaite","year":"2008","unstructured":"Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE (2008) A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 58(6):1810\u20131822. https:\/\/doi.org\/10.1002\/art.23501","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8831_CR97","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/1529-0131(200005)43:5<1054::AID-ANR14>3.0.CO;2-W","volume":"43","author":"KM McKown","year":"2000","unstructured":"McKown KM, Carbone LD, Bustillo J, Seyer JM, Kang AH, Postlethwaite AE (2000) Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 43(5):1054\u20131061. https:\/\/doi.org\/10.1002\/1529-0131(200005)43:5%3c1054::AID-ANR14%3e3.0.CO;2-W","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8831_CR98","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0304-4165(93)90123-p","volume":"1156","author":"I Granot","year":"1993","unstructured":"Granot I, Halevy O, Hurwitz S, Pines M (1993) Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1156(2):107\u2013112. https:\/\/doi.org\/10.1016\/0304-4165(93)90123-p","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"8831_CR99","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/archsurg.1995.01430030027004","volume":"130","author":"ET Choi","year":"1995","unstructured":"Choi ET, Callow AD, Sehgal NL, Brown DM, Ryan US (1995) Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia. Arch Surg 130(3):257\u2013261. https:\/\/doi.org\/10.1001\/archsurg.1995.01430030027004","journal-title":"Arch Surg"},{"issue":"11","key":"8831_CR100","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1097\/00007890-199912150-00027","volume":"68","author":"A Nagler","year":"1999","unstructured":"Nagler A, Pines M (1999) Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 68(11):1806\u20131809. https:\/\/doi.org\/10.1097\/00007890-199912150-00027","journal-title":"Transplantation"},{"issue":"7","key":"8831_CR101","first-page":"1277","volume":"22","author":"A Silman","year":"1995","unstructured":"Silman A, Harrison M, Brennan P (1995) Is it possible to reduce observer variability in skin score assessment of scleroderma? The ad hoc International Group on the Assessment of Disease Outcome in Scleroderma. J Rheumatol 22(7):1277\u20131280","journal-title":"J Rheumatol"},{"issue":"13","key":"8831_CR102","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2165\/11207710-000000000-00000","volume":"71","author":"NJ Carter","year":"2011","unstructured":"Carter NJ (2011) Pirfenidone: in idiopathic pulmonary fibrosis. Drugs 71(13):1721\u20131732. https:\/\/doi.org\/10.2165\/11207710-000000000-00000","journal-title":"Drugs"},{"issue":"3","key":"8831_CR103","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00403-011-1184-2","volume":"304","author":"M Saito","year":"2012","unstructured":"Saito M, Yamazaki M, Maeda T, Matsumura H, Setoguchi Y, Tsuboi R (2012) Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction. Arch Dermatol Res 304(3):217\u2013222. https:\/\/doi.org\/10.1007\/s00403-011-1184-2","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"8831_CR104","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E (2016) An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol 43(9):1672\u20131679. https:\/\/doi.org\/10.3899\/jrheum.151322","journal-title":"J Rheumatol"},{"issue":"5","key":"8831_CR105","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","volume":"40","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S (2020) Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int 40(5):703\u2013710. https:\/\/doi.org\/10.1007\/s00296-020-04565-w","journal-title":"Rheumatol Int"},{"issue":"5","key":"8831_CR106","first-page":"627","volume":"128","author":"C Bernier","year":"2001","unstructured":"Bernier C, Dreno B (2001) Minocycline. Ann Dermatol Venereol 128(5):627\u2013637","journal-title":"Ann Dermatol Venereol"},{"issue":"10","key":"8831_CR107","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/1529-0131(200110)44:10<2235::aid-art385>3.0.co;2-a","volume":"44","author":"JR O'Dell","year":"2001","unstructured":"O\u2019Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF (2001) Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 44(10):2235\u20132241. https:\/\/doi.org\/10.1002\/1529-0131(200110)44:10%3c2235::aid-art385%3e3.0.co;2-a","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8831_CR108","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00403-002-0300-8","volume":"294","author":"U Anderegg","year":"2002","unstructured":"Anderegg U, Prieb J, Hildebrandt G, Saalbach A (2002) Minocycline does not alter collagen type I metabolism of dermal fibroblasts in culture. Arch Dermatol Res 294(3):103\u2013108. https:\/\/doi.org\/10.1007\/s00403-002-0300-8","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"8831_CR109","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.20036","volume":"50","author":"MD Mayes","year":"2004","unstructured":"Mayes MD, O\u2019Donnell D, Rothfield NF, Csuka ME (2004) Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 50(2):553\u2013557. https:\/\/doi.org\/10.1002\/art.20036","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8831_CR110","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1023\/a:1011990129437","volume":"15","author":"H Cohen","year":"1998","unstructured":"Cohen H, Solomon V, Alferiev IS, Breuer E, Ornoy A, Patlas N, Eidelman N, Hagele G, Golomb G (1998) Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharm Res 15(4):606\u2013613. https:\/\/doi.org\/10.1023\/a:1011990129437","journal-title":"Pharm Res"},{"issue":"3","key":"8831_CR111","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/ard.62.3.267","volume":"62","author":"LP Robertson","year":"2003","unstructured":"Robertson LP, Marshall RW, Hickling P (2003) Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 62(3):267\u2013269. https:\/\/doi.org\/10.1136\/ard.62.3.267","journal-title":"Ann Rheum Dis"},{"key":"8831_CR112","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-med-051914-022120","volume":"67","author":"AB Pernis","year":"2016","unstructured":"Pernis AB, Ricker E, Weng CH, Rozo C, Yi W (2016) Rho kinases in autoimmune diseases. Annu Rev Med 67:355\u2013374. https:\/\/doi.org\/10.1146\/annurev-med-051914-022120","journal-title":"Annu Rev Med"},{"issue":"3","key":"8831_CR113","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.tips.2010.12.006","volume":"32","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Gensch C, Liao JK (2011) Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 32(3):167\u2013173. https:\/\/doi.org\/10.1016\/j.tips.2010.12.006","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"8831_CR114","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1124\/pr.114.009381","volume":"67","author":"RS Knipe","year":"2015","unstructured":"Knipe RS, Tager AM, Liao JK (2015) The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev 67(1):103\u2013117. https:\/\/doi.org\/10.1124\/pr.114.009381","journal-title":"Pharmacol Rev"},{"issue":"1","key":"8831_CR115","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","volume":"8","author":"S Bhattacharyya","year":"2011","unstructured":"Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8(1):42\u201354. https:\/\/doi.org\/10.1038\/nrrheum.2011.149","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"8831_CR116","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1002\/art.23677","volume":"58","author":"A Akhmetshina","year":"2008","unstructured":"Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, Distler O, Schett G, Distler JH (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 58(8):2553\u20132564. https:\/\/doi.org\/10.1002\/art.23677","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8831_CR117","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/FJC.0b013e3182a3718f","volume":"62","author":"J Shi","year":"2013","unstructured":"Shi J, Wei L (2013) Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol 62(4):341\u2013354. https:\/\/doi.org\/10.1097\/FJC.0b013e3182a3718f","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"8831_CR118","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/acr.21622","volume":"64","author":"A Fava","year":"2012","unstructured":"Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, Boin F (2012) Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud\u2019s phenomenon. Arthritis Care Res (Hoboken) 64(6):925\u2013929. https:\/\/doi.org\/10.1002\/acr.21622","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"19","key":"8831_CR119","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989\u20132003. https:\/\/doi.org\/10.1056\/NEJMra0806188","journal-title":"N Engl J Med"},{"issue":"7","key":"8831_CR120","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/jdv.14914","volume":"32","author":"C Matucci-Cerinic","year":"2018","unstructured":"Matucci-Cerinic C, Nagaraja V, Prignano F, Kahaleh B, Bellando-Randone S (2018) The role of the dermatologist in Raynaud\u2019s phenomenon: a clinical challenge. J Eur Acad Dermatol Venereol 32(7):1120\u20131127. https:\/\/doi.org\/10.1111\/jdv.14914","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"8831_CR121","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","volume":"72","author":"M Roustit","year":"2013","unstructured":"Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud\u2019s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72(10):1696\u20131699. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202836","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8831_CR122","first-page":"298","volume":"74","author":"M Fischer","year":"1985","unstructured":"Fischer M, Reinhold B, Falck H, Torok M, Alexander K (1985) Topical nitroglycerin ointment in Raynaud\u2019s phenomenon. Z Kardiol 74(5):298\u2013302","journal-title":"Z Kardiol"},{"issue":"7","key":"8831_CR123","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","volume":"34","author":"LS Teh","year":"1995","unstructured":"Teh LS, Manning J, Moore T, Tully MP, O\u2019Reilly D, Jayson MI (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud\u2019s phenomenon. Br J Rheumatol 34(7):636\u2013641. https:\/\/doi.org\/10.1093\/rheumatology\/34.7.636","journal-title":"Br J Rheumatol"},{"issue":"5","key":"8831_CR124","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/archderm.119.5.396","volume":"119","author":"LL Peterson","year":"1983","unstructured":"Peterson LL, Vorhies C (1983) Raynaud\u2019s syndrome. Treatment with sublingual administration of nitroglycerin, swinging arm maneuver, and biofeedback training. Arch Dermatol 119(5):396\u2013399. https:\/\/doi.org\/10.1001\/archderm.119.5.396","journal-title":"Arch Dermatol"},{"issue":"8263","key":"8831_CR125","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/s0140-6736(82)90215-x","volume":"1","author":"AG Franks Jr","year":"1982","unstructured":"Franks AG Jr (1982) Topical glyceryl trinitrate as adjunctive treatment in Raynaud\u2019s disease. Lancet 1(8263):76\u201377. https:\/\/doi.org\/10.1016\/s0140-6736(82)90215-x","journal-title":"Lancet"},{"issue":"12","key":"8831_CR126","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1136\/annrheumdis-2012-201536","volume":"72","author":"LK Hummers","year":"2013","unstructured":"Hummers LK, Dugowson CE, Dechow FJ, Wise RA, Gregory J, Michalek J, Yenokyan G, McGready J, Wigley FM (2013) A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann Rheum Dis 72(12):1962\u20131967. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201536","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8831_CR127","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/art.24351","volume":"60","author":"L Chung","year":"2009","unstructured":"Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM (2009) MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud\u2019s phenomenon: a randomized, controlled trial. Arthritis Rheum 60(3):870\u2013877. https:\/\/doi.org\/10.1002\/art.24351","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8831_CR128","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acr.20673","volume":"64","author":"D Giuggioli","year":"2012","unstructured":"Giuggioli D, Manfredi A, Colaci M, Lumetti F, Ferri C (2012) Scleroderma digital ulcers complicated by infection with fecal pathogens. Arthritis Care Res (Hoboken) 64(2):295\u2013297. https:\/\/doi.org\/10.1002\/acr.20673","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"8831_CR129","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acr.22018","volume":"65","author":"T Tingey","year":"2013","unstructured":"Tingey T, Shu J, Smuczek J, Pope J (2013) Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 65(9):1460\u20131471. https:\/\/doi.org\/10.1002\/acr.22018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"8831_CR130","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"JH Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50(12):3985\u20133993. https:\/\/doi.org\/10.1002\/art.20676","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8831_CR131","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70(1):32\u201338. https:\/\/doi.org\/10.1136\/ard.2010.130658","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"8831_CR132","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1001\/jama.2016.5258","volume":"315","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, Matucci-Cerinic M, Furst DE, Investigators D, Investigators D (2016) Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA 315(18):1975\u20131988. https:\/\/doi.org\/10.1001\/jama.2016.5258","journal-title":"JAMA"},{"issue":"3","key":"8831_CR133","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10238-019-00553-y","volume":"19","author":"S Negrini","year":"2019","unstructured":"Negrini S, Magnani O, Matucci-Cerinic M, Carignola R, Data V, Montabone E, Santaniello A, Adorni G, Murdaca G, Puppo F, Indiveri F, Della Rossa A, D\u2019Ascanio A, Barsotti S, Giuggioli D, Ferri C, Lumetti F, Bosello SL, Canestrari G, Bellando Randone S, Bruni C, Guiducci S, Battaglia E, De Andres MI, Russo AA, Beretta L (2019) Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin Exp Med 19(3):357\u2013366. https:\/\/doi.org\/10.1007\/s10238-019-00553-y","journal-title":"Clin Exp Med"},{"issue":"3","key":"8831_CR134","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10067-019-04924-4","volume":"39","author":"M Hughes","year":"2020","unstructured":"Hughes M, Alcacer-Pitarch B, Gheorghiu AM, Praino E, Sandler RD, Tavor Y, Bruni C, Matucci-Cerinic M (2020) Digital ulcer debridement in systemic sclerosis: a systematic literature review. Clin Rheumatol 39(3):805\u2013811. https:\/\/doi.org\/10.1007\/s10067-019-04924-4","journal-title":"Clin Rheumatol"},{"issue":"4","key":"8831_CR135","first-page":"642","volume":"32","author":"ER Bogoch","year":"2005","unstructured":"Bogoch ER, Gross DK (2005) Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 32(4):642\u2013648","journal-title":"J Rheumatol"},{"key":"8831_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2020.04.006","author":"MG Guerra","year":"2020","unstructured":"Guerra MG, Fonseca DGD, Samoes B, Videira T, Pinto P (2020) Is botulinum toxin useful in systemic sclerosis related peripheral vasculopathy? A literature review. Reumatol Clin. https:\/\/doi.org\/10.1016\/j.reuma.2020.04.006","journal-title":"Reumatol Clin"},{"issue":"9","key":"8831_CR137","first-page":"1801","volume":"35","author":"A Abou-Raya","year":"2008","unstructured":"Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers. J Rheumatol 35(9):1801\u20131808","journal-title":"J Rheumatol"},{"issue":"11","key":"8831_CR138","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","volume":"54","author":"M Hughes","year":"2015","unstructured":"Hughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B, Baildam E, Denton CP, Herrick AL (2015) Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford) 54(11):2015\u20132024. https:\/\/doi.org\/10.1093\/rheumatology\/kev201","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"8831_CR139","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66(7):940\u2013944. https:\/\/doi.org\/10.1136\/ard.2006.066068","journal-title":"Ann Rheum Dis"},{"issue":"25 Suppl","key":"8831_CR140","doi-asserted-by":"publisher","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","volume":"62","author":"N Galie","year":"2013","unstructured":"Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A (2013) Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(25 Suppl):D60-72. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.031","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"8831_CR141","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11926-015-0560-x","volume":"18","author":"V Sobanski","year":"2016","unstructured":"Sobanski V, Launay D, Hachulla E, Humbert M (2016) Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Curr Rheumatol Rep 18(2):10. https:\/\/doi.org\/10.1007\/s11926-015-0560-x","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"8831_CR142","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","volume":"190","author":"MO Becker","year":"2014","unstructured":"Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, Witzenrath M, Kuhl AA, Heidecke H, Ghofrani HA, Tiede H, Schermuly RT, Nickel N, Hoeper MM, Lukitsch I, Gollasch M, Kuebler WM, Bock S, Burmester GR, Dragun D, Riemekasten G (2014) Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med 190(7):808\u2013817. https:\/\/doi.org\/10.1164\/rccm.201403-0442OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"8831_CR143","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1164\/rccm.201507-1456OC","volume":"192","author":"RL Rhee","year":"2015","unstructured":"Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM (2015) Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 192(9):1111\u20131117. https:\/\/doi.org\/10.1164\/rccm.201507-1456OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"8831_CR144","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.11-2212","volume":"142","author":"VF Tapson","year":"2012","unstructured":"Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galie N (2012) Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 142(6):1383\u20131390. https:\/\/doi.org\/10.1378\/chest.11-2212","journal-title":"Chest"},{"issue":"12","key":"8831_CR145","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11906-017-0796-0","volume":"19","author":"R El Yafawi","year":"2017","unstructured":"El Yafawi R, Wirth JA (2017) What is the role of oral prostacyclin pathway medications in pulmonary arterial hypertension management? Curr Hypertens Rep 19(12):97. https:\/\/doi.org\/10.1007\/s11906-017-0796-0","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"8831_CR146","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/s0735-1097(03)00463-7","volume":"41","author":"RJ Barst","year":"2003","unstructured":"Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R, Beraprost Study G (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41(12):2119\u20132125. https:\/\/doi.org\/10.1016\/s0735-1097(03)00463-7","journal-title":"J Am Coll Cardiol"},{"key":"8831_CR147","doi-asserted-by":"publisher","unstructured":"Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galie N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM (2017) Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 50 (2). doi:https:\/\/doi.org\/10.1183\/13993003.02493-2016","DOI":"10.1183\/13993003.02493-2016"},{"issue":"12","key":"8831_CR148","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896\u2013903. https:\/\/doi.org\/10.1056\/NEJMoa012212","journal-title":"N Engl J Med"},{"issue":"9","key":"8831_CR149","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, Investigators S (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369(9):809\u2013818. https:\/\/doi.org\/10.1056\/NEJMoa1213917","journal-title":"N Engl J Med"},{"key":"8831_CR150","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.rmed.2016.06.018","volume":"117","author":"A Fischer","year":"2016","unstructured":"Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, Nathan SD (2016) Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - a subgroup analysis of the ARIES-E clinical trial. Respir Med 117:254\u2013263. https:\/\/doi.org\/10.1016\/j.rmed.2016.06.018","journal-title":"Respir Med"},{"issue":"12","key":"8831_CR151","first-page":"2417","volume":"34","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, Simonneau G, Group SS (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34(12):2417\u20132422","journal-title":"J Rheumatol"},{"issue":"6","key":"8831_CR152","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.semarthrit.2016.12.003","volume":"46","author":"RE Pellar","year":"2017","unstructured":"Pellar RE, Pope JE (2017) Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Semin Arthritis Rheum 46(6):767\u2013774. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.12.003","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"8831_CR153","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clim.2015.09.010","volume":"161","author":"T Higuchi","year":"2015","unstructured":"Higuchi T, Kawaguchi Y, Takagi K, Tochimoto A, Ota Y, Katsumata Y, Ichida H, Hanaoka M, Kawasumi H, Tochihara M, Yamanaka H (2015) Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in patients with systemic sclerosis. Clin Immunol 161(2):333\u2013338. https:\/\/doi.org\/10.1016\/j.clim.2015.09.010","journal-title":"Clin Immunol"},{"issue":"2","key":"8831_CR154","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","volume":"76","author":"M Humbert","year":"2017","unstructured":"Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira PJ, Denton CP (2017) Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 76(2):422\u2013426. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209087","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"8831_CR155","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ, investigators A (2017) Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 76(7):1219\u20131227. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210236","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8831_CR156","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.39478","volume":"68","author":"MR Lammi","year":"2016","unstructured":"Lammi MR, Mathai SC, Saketkoo LA, Domsic RT, Bojanowski C, Furst DE, Steen VD, Pulmonary Hypertension A, Recognition of Outcomes in Scleroderma I (2016) Association between initial oral therapy and outcomes in systemic sclerosis-related pulmonary arterial hypertension. Arthritis Rheumatol 68(3):740\u2013748. https:\/\/doi.org\/10.1002\/art.39478","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"8831_CR157","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","volume":"43","author":"M Hudson","year":"2014","unstructured":"Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D, International Scleroderma Renal Crisis Study I (2014) Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 43(5):666\u2013672. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.09.008","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"8831_CR158","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13075-020-2141-2","volume":"22","author":"L Butikofer","year":"2020","unstructured":"Butikofer L, Varisco PA, Distler O, Kowal-Bielecka O, Allanore Y, Riemekasten G, Villiger PM, Adlercollaborators E, S (2020) ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. Arthritis Res Ther 22(1):59. https:\/\/doi.org\/10.1186\/s13075-020-2141-2","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"8831_CR159","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1053\/j.ajkd.2005.01.007","volume":"45","author":"WY Cheung","year":"2005","unstructured":"Cheung WY, Gibson IW, Rush D, Jeffery J, Karpinski M (2005) Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis 45(5):930\u2013934. https:\/\/doi.org\/10.1053\/j.ajkd.2005.01.007","journal-title":"Am J Kidney Dis"},{"issue":"10103","key":"8831_CR160","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"issue":"12","key":"8831_CR161","doi-asserted-by":"publisher","first-page":"102403","DOI":"10.1016\/j.autrev.2019.102403","volume":"18","author":"J Blagojevic","year":"2019","unstructured":"Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L (2019) Is there today a place for corticosteroids in the treatment of scleroderma? Autoimmun Rev 18(12):102403. https:\/\/doi.org\/10.1016\/j.autrev.2019.102403","journal-title":"Autoimmun Rev"},{"issue":"5","key":"8831_CR162","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jaad.2010.09.006","volume":"65","author":"BA Zwischenberger","year":"2011","unstructured":"Zwischenberger BA, Jacobe HT (2011) A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 65(5):925\u2013941. https:\/\/doi.org\/10.1016\/j.jaad.2010.09.006","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8831_CR163","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","volume":"38","author":"O Distler","year":"2016","unstructured":"Distler O, Cozzio A (2016) Systemic sclerosis and localized scleroderma\u2013current concepts and novel targets for therapy. Semin Immunopathol 38(1):87\u201395. https:\/\/doi.org\/10.1007\/s00281-015-0551-z","journal-title":"Semin Immunopathol"},{"issue":"3","key":"8831_CR164","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2165\/00128071-200910030-00004","volume":"10","author":"EB Kroft","year":"2009","unstructured":"Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM (2009) Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 10(3):181\u2013187. https:\/\/doi.org\/10.2165\/00128071-200910030-00004","journal-title":"Am J Clin Dermatol"},{"issue":"2 Pt 1","key":"8831_CR165","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0190-9622(98)70077-5","volume":"39","author":"BB Cunningham","year":"1998","unstructured":"Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS (1998) Topical calcipotriene for morphea\/linear scleroderma. J Am Acad Dermatol 39(2 Pt 1):211\u2013215. https:\/\/doi.org\/10.1016\/s0190-9622(98)70077-5","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"8831_CR166","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000335560","volume":"223","author":"E Pope","year":"2011","unstructured":"Pope E, Doria AS, Theriault M, Mohanta A, Laxer RM (2011) Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Dermatology 223(4):363\u2013369. https:\/\/doi.org\/10.1159\/000335560","journal-title":"Dermatology"},{"issue":"1","key":"8831_CR167","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/bjd.13544","volume":"173","author":"EA Gordon Spratt","year":"2015","unstructured":"Gordon Spratt EA, Gorcey LV, Soter NA, Brauer JA (2015) Phototherapy, photodynamic therapy and photopheresis in the treatment of connective-tissue diseases: a review. Br J Dermatol 173(1):19\u201330. https:\/\/doi.org\/10.1111\/bjd.13544","journal-title":"Br J Dermatol"},{"issue":"3","key":"8831_CR168","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","volume":"54","author":"A Kreuter","year":"2006","unstructured":"Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T (2006) A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 54(3):440\u2013447. https:\/\/doi.org\/10.1016\/j.jaad.2005.11.1063","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8831_CR169","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jaad.2013.10.018","volume":"70","author":"R Vasquez","year":"2014","unstructured":"Vasquez R, Jabbar A, Khan F, Buethe D, Ahn C, Jacobe H (2014) Recurrence of morphea after successful ultraviolet al phototherapy: a cohort study. J Am Acad Dermatol 70(3):481\u2013488. https:\/\/doi.org\/10.1016\/j.jaad.2013.10.018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"8831_CR170","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1097\/PRS.0000000000006291","volume":"144","author":"AL Strong","year":"2019","unstructured":"Strong AL, Rubin JP, Kozlow JH, Cederna PS (2019) Fat grafting for the treatment of scleroderma. Plast Reconstr Surg 144(6):1498\u20131507. https:\/\/doi.org\/10.1097\/PRS.0000000000006291","journal-title":"Plast Reconstr Surg"},{"issue":"12","key":"8831_CR171","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/j.1524-4725.2008.34343.x","volume":"34","author":"MR Roh","year":"2008","unstructured":"Roh MR, Jung JY, Chung KY (2008) Autologous fat transplantation for depressed linear scleroderma-induced facial atrophic scars. Dermatol Surg 34(12):1659\u20131665. https:\/\/doi.org\/10.1111\/j.1524-4725.2008.34343.x","journal-title":"Dermatol Surg"},{"issue":"3","key":"8831_CR172","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1203475415624912","volume":"20","author":"EZ Barin","year":"2016","unstructured":"Barin EZ, Cinal H, Cakmak MA, Tan O (2016) Treatment of linear scleroderma (en Coup de Sabre) with dermal fat grafting. J Cutan Med Surg 20(3):269\u2013271. https:\/\/doi.org\/10.1177\/1203475415624912","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"8831_CR173","first-page":"74","volume":"13","author":"KS Ibler","year":"2015","unstructured":"Ibler KS, Gramkow C, Siemssen PA (2015) Autologous fat transplantation for the treatment of linear scleroderma en coup de sabre. Skinmed 13(1):74\u201376","journal-title":"Skinmed"},{"issue":"11","key":"8831_CR174","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3727\/096368914X685636","volume":"24","author":"N Del Papa","year":"2015","unstructured":"Del Papa N, Di Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A, Sambataro G, Ferraresi R, Vitali C (2015) Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant 24(11):2297\u20132305. https:\/\/doi.org\/10.3727\/096368914X685636","journal-title":"Cell Transplant"},{"issue":"5","key":"8831_CR175","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3727\/096368912X639017","volume":"22","author":"N Scuderi","year":"2013","unstructured":"Scuderi N, Ceccarelli S, Onesti MG, Fioramonti P, Guidi C, Romano F, Frati L, Angeloni A, Marchese C (2013) Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant 22(5):779\u2013795. https:\/\/doi.org\/10.3727\/096368912X639017","journal-title":"Cell Transplant"},{"issue":"5","key":"8831_CR176","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archderm.1994.01690050133027","volume":"130","author":"P Joly","year":"1994","unstructured":"Joly P, Bamberger N, Crickx B, Belaich S (1994) Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 130(5):663\u2013664","journal-title":"Arch Dermatol"},{"issue":"1","key":"8831_CR177","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0022-3476(00)90056-8","volume":"136","author":"Y Uziel","year":"2000","unstructured":"Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM (2000) Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 136(1):91\u201395. https:\/\/doi.org\/10.1016\/s0022-3476(00)90056-8","journal-title":"J Pediatr"},{"issue":"7","key":"8831_CR178","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.30264","volume":"63","author":"F Zulian","year":"2011","unstructured":"Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, Alessio M, La Torre F, Podda RA, Gerloni V, Cutrone M, Belloni-Fortina A, Paradisi M, Martino S, Perilongo G (2011) Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 63(7):1998\u20132006. https:\/\/doi.org\/10.1002\/art.30264","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8831_CR179","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1365-2133.2006.07497.x","volume":"155","author":"L Weibel","year":"2006","unstructured":"Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI (2006) Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol 155(5):1013\u20131020. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07497.x","journal-title":"Br J Dermatol"},{"key":"8831_CR180","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaut.2018.02.001","volume":"91","author":"ILA Bodewes","year":"2018","unstructured":"Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, Tas L, Huizinga R, Dalm V, van Hagen PM, Groot N, Kamphuis S, van Daele PLA, Versnel MA (2018) TBK1: A key regulator and potential treatment target for interferon positive Sjogren\u2019s syndrome, systemic lupus erythematosus and systemic sclerosis. J Autoimmun 91:97\u2013102. https:\/\/doi.org\/10.1016\/j.jaut.2018.02.001","journal-title":"J Autoimmun"},{"key":"8831_CR181","doi-asserted-by":"publisher","first-page":"108364","DOI":"10.1016\/j.clim.2020.108364","volume":"213","author":"R Marrapodi","year":"2020","unstructured":"Marrapodi R, Pellicano C, Radicchio G, Leodori G, Colantuono S, Iacolare A, Gigante A, Visentini M, Rosato E (2020) CD21(low) B cells in systemic sclerosis: a possible marker of vascular complications. Clin Immunol 213:108364. https:\/\/doi.org\/10.1016\/j.clim.2020.108364","journal-title":"Clin Immunol"},{"key":"8831_CR182","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clim.2017.07.012","volume":"186","author":"A Sharabi","year":"2018","unstructured":"Sharabi A, Kasper IR, Tsokos GC (2018) The serine\/threonine protein phosphatase 2A controls autoimmunity. Clin Immunol 186:38\u201342. https:\/\/doi.org\/10.1016\/j.clim.2017.07.012","journal-title":"Clin Immunol"},{"key":"8831_CR183","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2017.05.013","volume":"184","author":"E Ugor","year":"2017","unstructured":"Ugor E, Simon D, Almanzar G, Pap R, Najbauer J, Nemeth P, Balogh P, Prelog M, Czirjak L, Berki T (2017) Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis. Clin Immunol 184:54\u201362. https:\/\/doi.org\/10.1016\/j.clim.2017.05.013","journal-title":"Clin Immunol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-020-08831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-020-08831-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-020-08831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T04:26:53Z","timestamp":1649478413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-020-08831-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":183,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["8831"],"URL":"https:\/\/doi.org\/10.1007\/s12016-020-08831-4","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"21 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}